Refractory Anemia with Excess Blasts Type 1 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Refractory Anemia with Excess Blasts Type 1

MalaCards integrated aliases for Refractory Anemia with Excess Blasts Type 1:

Name: Refractory Anemia with Excess Blasts Type 1 ⁵⁸

Refractory Anemia with Excess Blasts I ⁷¹

Raeb-1 ⁵⁸

Characteristics:

Orphanet epidemiological data:

⁵⁸

refractory anemia with excess blasts type 1
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Neoplasms of uncertain or unknown behaviour

Myelodysplastic syndromes

Refractory anaemia with excess of blasts

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

ICD10 via Orphanet ³³ D46.2

UMLS via Orphanet ⁷² C1318550

Orphanet ⁵⁸ ORPHA100019

UMLS ⁷¹ C1318550

Sources

Summaries for Refractory Anemia with Excess Blasts Type 1

MalaCards based summary : Refractory Anemia with Excess Blasts Type 1, also known as refractory anemia with excess blasts i, is related to myelodysplastic syndrome. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and bone.

Sources

Related Diseases for Refractory Anemia with Excess Blasts Type 1

Diseases in the Refractory Anemia with Excess Blasts Type 2 family:

Refractory Anemia with Excess Blasts Type 1

Diseases related to Refractory Anemia with Excess Blasts Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

#	Related Disease	Score	Top Affiliating Genes
1	myelodysplastic syndrome	10.3

Sources

Symptoms & Phenotypes for Refractory Anemia with Excess Blasts Type 1

Sources

Drugs & Therapeutics for Refractory Anemia with Excess Blasts Type 1

Drugs for Refractory Anemia with Excess Blasts Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Lenograstim

Approved, Investigational

Phase 2, Phase 3

135968-09-1

2

Cyclophosphamide

Approved, Investigational

Phase 2, Phase 3

50-18-0, 6055-19-2

2907

Synonyms:

(-)-Cyclophosphamide

(+-)-Cyclophosphamide

(RS)-Cyclophosphamide

1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine

1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin

2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide

4-Hydroxy-cyclophosphan-mamophosphatide

50-18-0

60007-95-6

6055-19-2 (monohydrate)

75526-90-8

AC1L1EQQ

AI3-26198

Anhydrous cyclophosphamide

Anhydrous, cyclophosphamide

ASTA

Asta B 518

ASTA B518

B 518

B-518

bis(2-Chloroethyl)phosphami de cyclic propanolamide

bis(2-Chloroethyl)phosphamide cyclic propanolamide ester

Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester

BRN 0011744

BSPBio_002099

C 0768

C07888

C7H15Cl2N2O2P

CB 4564

CB-4564

CCRIS 188

CHEBI:4027

CHEMBL32520

CHEMBL88

Ciclofosfamida

Ciclofosfamida [INN-Spanish]

Ciclofosfamide

Ciclophosphamide

Ciclophosphamide [INN]

CID2907

Clafen

Claphene

CP

CPA

CTX

CY

Cycloblastin

Cyclophosphamid

cyclophosphamide

Cyclophosphamide

Cyclophosphamide (anhydrous form)

Cyclophosphamide (anhydrous)

Cyclophosphamide (INN)

Cyclophosphamide (TN)

Cyclophosphamide anhydrous

Cyclophosphamide monohydrate

Cyclophosphamide Monohydrate

Cyclophosphamide Sterile

Cyclophosphamide, (+-)-Isomer

Cyclophosphamide, (R)-isomer

Cyclophosphamide, (S)-isomer

Cyclophosphamides

Cyclophosphamidum

Cyclophosphamidum [INN-Latin]

Cyclophosphan

Cyclophosphane

Cyclophosphanum

Cyclophosphoramide

Cyclostin

Cyklofosfamid

Cyklofosfamid [Czech]

Cytophosphan

Cytophosphane

Cytoxan

Cytoxan (TN)

Cytoxan Lyoph

D,L-Cyclophosphamide

D07760

DB00531

DivK1c_000246

EINECS 200-015-4

Endoxan

Endoxan R

Endoxana

Endoxanal

Endoxan-Asta

Endoxane

Enduxan

EU-0100238

Genoxal

Hexadrin

HMS2090A12

HSDB 3047

IDI1_000246

KBio1_000246

KBio2_001338

KBio2_003906

KBio2_006474

KBio3_001319

KBioGR_000888

KBioSS_001338

Lopac0_000238

Lopac-C-0768

LS-1302

LS-99787

Lyophilized Cytoxan

Mitoxan

MolPort-001-783-420

Monohydrate, cyclophosphamide

N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

NCGC00015209-01

NCGC00015209-03

NCGC00015209-06

NCGC00091741-02

NCGC00091741-03

NCI60_002097

NCI-C04900

Neosar

NINDS_000246

NSC 26271

NSC26271

NSC-26271

NSC273033

NSC273034

Occupation, cyclophosphamide exposure

Procytox

RCRA waste no. U058

Rcra waste number U058

Rcra Waste Number U058

Revimmune

S1217_Selleck

Semdoxan

Sendoxan

Senduxan

SK 20501

SPBio_001071

Spectrum_000858

Spectrum2_001146

Spectrum3_000370

Spectrum4_000304

Spectrum5_000795

STK177249

STOCK2S-91217

UNII-6UXW23996M

WLN: T6MPOTJ BO BN2G2G

Zyklophosphamid

Zyklophosphamid [German]

3

Sargramostim

Approved, Investigational

Phase 2, Phase 3

83869-56-1, 123774-72-1

Synonyms:

123774-72-1

D05803

Leukine

Leukine (TN)

Recombinant human granulocyte-macrophage colony stimulating factor

rGM-CSF

rHu GM-CSF

Sargramostim

Sargramostim (genetical recombination)

Sargramostim (genetical recombination) (JAN)

Sargramostim (USAN/INN)

4

Busulfan

Approved, Investigational

Phase 2, Phase 3

55-98-1

2478

Synonyms:

1, {4-Bis[methanesulfonoxy]butane}

1, 4-Dimethanesulfonoxybutane

1, 4-Dimethylsulfonoxybutane

1,4-Bis(methanesulfonoxy)butane

1,4-Bis(methanesulfonyloxy)butane

1,4-Bis(methanesulphonoxy)butane

1,4-Bis[methanesulfonoxy]butane

1,4-Butanedi yl dimethanesulfonate

1,4-Butanediol dimethanesulfonate

1,4-BUTANEDIOL DIMETHANESULFONATE

1,4-Butanediol dimethanesulfonic acid

1,4-Butanediol dimethanesulphonate

1,4-Butanediol dimethanesulphonic acid

1,4-Butanediol dimethylsulfonate

1,4-Butanediol, dimethanesulfonate

1,4-Butanediol, dimethanesulphonate

1,4-Butanediyl dimethanesulfonate

1,4-Di(methylsulfonoxy)butane

1,4-Dimesyloxybutane

1,4-Dimethane sulfonyl oxybutane

1,4-Dimethanesulfonoxybutane

1,4-Dimethanesulfonoxylbutane

1,4-Dimethanesulfonyloxybutane

1,4-Dimethanesulphonoxybutane

1,4-Dimethanesulphonyloxybutane

1,4-Dimethylsulfonoxybutane

1,4-Dimethylsulfonyloxybutane

2041 C. B

2041 C. B.

2041 C.B

2041 C.B.

4-((Methylsulfonyl)oxy)butyl methanesulfonate

4-methylsulfonyloxybutyl methanesulfonate

55-98-1

AC-198

AC1L1DRQ

AC1Q4GRQ

acid, tetramethylene ester

AI3-25012

AKOS003614975

alkylating agent: crosslinks guanine residues

Ambap55-98-1

AN 33501

B1022

B2635_FLUKA

B2635_SIGMA

Bisulfex

Bisulphex

BRN 1791786

BSPBio_001920

Busilvex

busulfan

Busulfan

BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)

Busulfan (JP15/USP/INN)

Busulfan [INN:JAN]

Busulfan glaxosmithkline brand

Busulfan GlaxoSmithKline Brand

Busulfan orphan brand

Busulfan Orphan Brand

Busulfan wellcome

Busulfan Wellcome

Busulfan wellcome brand

Busulfan Wellcome Brand

Busulfano

Busulfano [INN-Spanish]

Busulfanum

Busulfanum [INN-Latin]

Busulfex

Busulphan

Busulphane

Busulphano

Busulphanum

butane-1,4-diyl dimethanesulfonate

Butanedioldimethanesulfonate

Buzulfan

C.B. 2041

C6H14O6S2

CB 2041

CCRIS 418

CHEBI:28901

CHEMBL820

CID2478

Citosulfan

CPD000058613

D002066

D00248

DB01008

DivK1c_000847

EINECS 200-250-2

FT-0083567

G.T. 41

glaxo Wellcome brand OF busulfan

Glaxo Wellcome Brand of Busulfan

GlaxoSmithKline brand OF busulfan

GlaxoSmithKline Brand of Busulfan

Glyzophrol

GT 2041

GT 41

HMS1920I07

HMS2091O09

HMS502K09

HSDB 7605

I09-1371

IDI1_000847

InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

KBio1_000847

KBio2_000512

KBio2_003080

KBio2_005648

KBio3_001420

KBioGR_000698

KBioSS_000512

Leucosulfan

Leucosulphan

LS-1358

Mablin

Methanesulfonic

Methanesulfonic acid, tetram ethylene ester

Methanesulfonic acid, tetramethylene ester

Mielevcin

Mielosan

Mielucin

Milecitan

Mileran

Misulban

Mitosan

Mitostan

MLS001076666

MolPort-001-783-406

Myeleukon

Myeloleukon

Myelosan

Myelosanum

Mylecytan

Myleran

Myléran

MYLERAN (TN)

Myleran tablets

Myleran Tablets

Myleran, Busulfex, Busulfan

Mylerlan

n-Butane-1,3-di(methylsulfonate)

N-Butane-1,3-di(methylsulfonate)

NCGC00090905-01

NCGC00090905-02

NCGC00090905-03

NCGC00090905-04

NCGC00090905-05

NCGC00090905-06

NCGC00090905-07

NCI60_041640

NCI-C01592

NCIMech_000192

NINDS_000847

NSC 750

NSC750

NSC-750

NSC-750sulphabutin

Orphan brand OF busulfan

Orphan Brand of Busulfan

Prestwick_989

S1692_Selleck

SAM002554887

SMR000058613

SPBio_000253

Spectrum_000092

SPECTRUM1500152

Spectrum2_000067

Spectrum3_000320

Spectrum4_000259

Spectrum5_000928

ST50825921

Sulfabutin

Sulfabutin (VAN)

Sulphabutin

Tetramethylene {bis[methanesulfonate]}

Tetramethylene bis(methanesulfonate)

Tetramethylene bis(methanesulfonic acid)

Tetramethylene bis(methanesulphonate)

Tetramethylene bis(methanesulphonic acid)

Tetramethylene bis[methanesulfonate]

Tetramethylene dimethane sulfonate

Tetramethylene Dimethane Sulfonate

Tetramethylenester kyseliny methansulfonove

Tetramethylenester Kyseliny Methansulfonove

Tetramethylenester kyseliny methansulfonove [Czech]

UNII-G1LN9045DK

Wellcome brand OF busulfan

Wellcome Brand of Busulfan

Wellcome, busulfan

Wellcome, Busulfan

WLN: WS1&O4OSW1

X 149

5

Decitabine

Approved, Investigational

Phase 3

2353-33-5

451668

Synonyms:

2353-33-5

2'-Deoxy-5-azacytidine

4-amino-1-(2-Deoxy-b-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one

4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one

4-amino-1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one

4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one

4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one

4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one

4-amino-1-(2-Deoxy-β-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one

4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one

5A2dc

5-Aza-2&prime

5-aza-2'-deoxycytidine

5-aza-2-deoxycytidine

5-Aza-2'-deoxycytidine

5-aza-CdR

5-aza-dC

5-AZAdC

5-azadeoxycytidine

5-Azadeoxycytidine

5-Deoxy-2&prime

5-Deoxyazacytidine

A3656_SIGMA

AC-1135

AC1L9PS9

-azacytidine

Azadc

AzadC

AzadC compound

CHEBI:50131

CHEMBL1201129

CID451668

D03665

DAC

Dacogen

Dacogen (TN)

Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine

DB01262

Decitabina

Decitabine

Decitabine (USAN/INN)

Decitabine mesylate

-Deoxycytidine

Dezocitidine

E-7373

FT-0082622

MLS001332587

MLS001332588

MolMap_000063

NCGC_5ADOC

NSC127716

NSC-127716

S1200_Selleck

SBB066121

SMR000857076

TL8001944

6

Azacitidine

Approved, Investigational

Phase 3

320-67-2

9444

Synonyms:

2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one

320-67-2

4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one

4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz

4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one

4-amino-1-b-D-Ribofuranosyl-S-triazin-2(1H)-one

4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one

4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one

4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one

4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one

4-amino-1-beta-D-Ribofuranosyl-S-triazin-2(1H)-one

4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one

4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one

4-amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one

5 Azacytidine

5 AZC

5-AC

5AzaC

5-AZAC

5-azacitidine

5-aza-CR

5-azacytidine

5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine

5-AZCR

A 2385

A1287_SIGMA

A2385_SIGMA

AC1L1T1Y

Antibiotic U 18496

Azacitidina

Azacitidina [INN-Spanish]

Azacitidine

Azacitidine (JAN/USAN/INN)

Azacitidine [USAN:INN]

Azacitidinum

Azacitidinum [INN-Latin]

Azacytidine

BCBcMAP01_000083

BRN 0620461

BSPBio_003157

C11262

CCRIS 60

CHEBI:2038

CHEMBL1489

CID9444

cMAP_000082

CPD000857239

D001374

D03021

DB00928

DivK1c_000125

EINECS 206-280-2

EU-0100035

FT-0081170

HMS1921J22

HMS2092D08

HMS500G07

HSDB 6879

IDI1_000125

InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1

Jsp005945

KBio1_000125

KBio2_001742

KBio2_002556

KBio2_004310

KBio2_005124

KBio2_006878

KBio2_007692

KBio3_002657

KBio3_003034

KBioGR_001444

KBioGR_002556

KBioSS_001742

KBioSS_002565

Ladakamycin

Lopac0_000035

LS-1189

MLS001333121

MLS001333122

MLS002153249

MolMap_000062

mylo sar

Mylosar

NCGC00090851-01

NCGC00090851-02

NCGC00090851-03

NCGC00090851-04

NCGC00090851-08

NCGC00178234-01

NCI-C01569

NINDS_000125

NS-17

NSC 102816

NSC102816

NSC-102816

Pharmion brand OF azacitidine

Pharmion Brand of Azacitidine

pyrimidine antimetabolite: inhibits nucleic acid replication

S1782_Selleck

SAM002264595

SMR000857239

SPBio_000892

Spectrum_001262

SPECTRUM1502111

Spectrum2_000786

Spectrum3_001509

Spectrum4_000922

Spectrum5_001166

ST056940

s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)

TL80073599

U 18496

U-18496

UNII-M801H13NRU

Vidaza

Vidaza (TN)

wr 183027

WR-183027

ZINC03861768

7

Molgramostim

Investigational

Phase 2, Phase 3

99283-10-0

8

Adjuvants, Immunologic

Phase 2, Phase 3

9

Antirheumatic Agents

Phase 2, Phase 3

10

Protein Kinase Inhibitors

Phase 3

11

ON 01910

Phase 3

12

Lenalidomide

Approved

Phase 2

191732-72-6

216326

Synonyms:

191732-72-6

1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline

1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline

3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione

3-(4-amino-1-Oxoisoindolin-2-yl)piperidine-2,6-dione

3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione

3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione

3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione

346670-73-3

443912-14-9

AC1L50II

AC-914

AKOS005146276

ALBB-015321

Bio-0168

C467567

CC 5013

CC5013

CC-5013

CC-5013, Revlimid, Lenalidomide

CDC 501

CDC-501

CDC-5013

Celgene brand of lenalidomide

Celgene brand OF lenalidomide

CHEMBL848

CID216326

D04687

DB00480

EC-000.2340

ENMD-0997

I06-0831

IMID-1

IMiD3

IMiD3 cpd

IMiD3 CPD

IMID-5013

Lenalidomida

lenalidomide

Lenalidomide

Lenalidomide (USAN/INN)

Lenalidomide [USAN]

LS-184040

MolPort-003-848-370

NCGC00167491-01

NSC747972

Revamid

Revimid

Revlimid

Revlimid (Celgene)

Revlimid (TN)

S1029_Selleck

STK639603

Thalidomide analog CC-5013

UNII-F0P408N6V4

13

Melphalan

Approved

Phase 2

148-82-3

460612 4053

Synonyms:

(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid

(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid

148-82-3

3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine

3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine

3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine

3025 c.b

3025 C.B.

3223-07-2

3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine

3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine

4-(Bis(2-chloroethyl)amino)-L-phenylalanine

4-(Bis(2-chloroethyl)amino)phenylalanine

4-[Bis(2-chloroethyl)amino]-L-phenylalanine

4-[Bis-(2-chloroethyl)amino]-L-phenylalanine

4-14-00-01689 (Beilstein Handbook Reference)

AC1LA2OE

Alanine Nitrogen Mustard

Alkeran

ALKERAN (TN)

AmbotzHAA1563

At-290

AY3360000

BIDD:GT0044

BRD-K87827419-001-02-8

BRN 2816456

BSPBio_002407

C13H18Cl2N2O2

CB 3025

CB-3025

CCRIS 374

CHEBI:165415

CHEBI:28876

CHEMBL852

CID460612

D00369

DivK1c_000653

EINECS 205-726-3

HMS2090B09

HMS2091B16

HMS502A15

HSDB 3234

IDI1_000653

KBio1_000653

KBio2_000877

KBio2_003445

KBio2_006013

KBio3_001627

KBioGR_001284

KBioSS_000877

L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine

L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine

L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine

Levofalan

Levofolan

Levopholan

L-PAM

L-Phenylalanine mustard

LS-15868

LS-865

L-Sarcolysin

L-Sarcolysine

L-Sarkolysin

M2011_SIGMA

Medphalan

Melfalan

Melfalano

Melfalano [INN-Spanish]

melphalan

Melphalan

Melphalan (JP15/USP/INN)

MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))

Melphalan [USAN:INN:BAN:JAN]

Melphalanum

Melphalanum [INN-Latin]

Mephalan

Merphalan

MLS001333666

MLS002153368

MolPort-003-665-535

Mustard, phenylalanine

NCGC00090757-01

NCGC00090757-02

NCGC00090757-03

NCI-C04853

NINDS_000653

NIOSH/AY3360000

NSC 241286

NSC 8806

NSC241286

NSC8806

NSC-8806

P-Bis(b-chloroethyl)aminophenylalanine

p-Bis(beta-chloroethyl)aminophenylalanine

P-Bis(beta-chloroethyl)aminophenylalanine

P-Bis(β-chloroethyl)aminophenylalanine

p-Di-(2-chloroethyl)amino-L-phenylalanine

P-Di-(2-chloroethyl)amino-L-phenylalanine

Phenylalanine mustard

phenylalanine nitrogen mu stard

Phenylalanine nitrogen mustard

p-L-Sarcolysin

P-L-Sarcolysin

p-L-sarcolysine

p-N,N-bis(2-chloroethyl)amino-L-phenylalanine

P-N,N-Bis(2-chloroethyl)amino-L-phenylalanine

p-N-Bis(2-chloroethyl)amino-L-phenylalanine

P-N-Bis(2-chloroethyl)amino-L-phenylalanine

p-N-di(chloroethyl)aminophenylala nine

p-N-Di(chloroethyl)aminophenylalanine

Prestwick_1006

RCRA waste no. U150

Rcra waste number U150

Sarcolysine

Sarkolysin

SK-15673

SMP2_000174

SMR000058720

SPBio_000287

Spectrum_000397

SPECTRUM1500382

Spectrum2_000074

Spectrum3_000684

Spectrum4_000882

Spectrum5_001601

TL8001065

TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)

TRANSGENIC MODEL EVALUATION (MELPHALAN)

UNII-Q41OR9510P

14

Alkylating Agents

Phase 2

15

Immunosuppressive Agents

Phase 2

16

Immunologic Factors

Phase 2

17

Angiogenesis Inhibitors

Phase 2

18

Cytarabine

Approved, Experimental, Investigational

Phase 1

147-94-4, 65-46-3

6253

Synonyms:

(beta-D-Arabinofuranosyl)cytosine

1-.beta.-D-arabinofuranosyl-cytosine

147-94-4

1-Arabinofuranosylcytosine

1-b-D-Arabinofuranosylcytosine

1beta -Arabinofuranasylcytosine

1-beta -D-Arabinofaranosylcytosine

1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone

1beta -D-Arabinofuranosylcytosine

1-beta -D-Arabinofuranosylcytosine

1beta -D-Arabinosylcytosine

1beta-Arabinofuranasylcytosine

1-beta-D-Arabinofaranosylcytosine

1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone

1beta-D-Arabinofuranosylcytosine

1-beta-D-Arabinofuranosylcytosine

1-beta-D-Arabinofuranosyl-cytosine

1-beta-D-Arabinofuranosylcytosine, cytosine arabinoside

1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside

1beta-D-Arabinosylcytosine

1-beta-D-Arabinosylcytosine

1-beta-D-Arabinosyl-cytosine

1-beta-D-Ribofuranosylcytosine

1-β-D-arabinofuranosylcytosine

1β-D-ribofuranosylcytosine

2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]

2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl

30399_FLUKA

4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin

4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin

4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]

4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidine

4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine

4-amino-1-b-D-Arabinofuranosyl-2(1H)-pyrimidinone

4-amino-1-b-D-Arabinofuranosyl-2-(1H)-pyrimidinone

4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone

4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon

4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]

4-amino-1-beta-D-Arabinofuranosyl-2(1H)-pyrimidinone

4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone

4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one

4-amino-1-beta-D-Arabinofuranosylpyrimidin-2(1H)-one

4-amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone

4-amino-1β-D-ribofuranosyl-2(1H)-pyrimidinone

4-amino-1-β-D-ribofuranosylpyrimidin-2(1H)-one

69-74-9 (hydrochloride)

AC-1075

AC1L1M4F

AC1Q52OJ

AI3-52329

Alexan

AR3

Arabinocytidine

Arabinofuranosylcytosine

Arabinoside, cytosine

Arabinosyl Cytosine

Arabinosylcytosine

Arabitin

AraC

Ara-C

Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine

Aracytidine

Ara-Cytidine

Aracytin

Aracytine

Arafcyt

beta -Arabinosylcytosine

beta -Cytosine arabinoside

beta -D-Arabinosylcytosine

beta-Ara c

beta-Ara C

beta-Arabinosylcytosine

beta-Cytosine arabinoside

Beta-cytosine arabinoside

beta-D-Arabinosylcytosine

BIDD:GT0371

BIDD:PXR0139

BTB15125

C02961

C1768_SIGMA

C2035

C9H13N3O5

CCRIS 913

CHEBI:28680

CHEMBL803

CHX 3311

CID6253

Citarabina

Citarabina [INN-Spanish]

Citidina

CPD000449317

Cytarabin

Cytarabina

cytarabine

Cytarabine

Cytarabine (JP15/USP/INN)

CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)

Cytarabine [USAN:INN:BAN:JAN]

Cytarabine hydrochloride

cytarabine liposome injection

Cytarabine liposome injection

Cytarabinoside

Cytarabinum

Cytarabinum [INN-Latin]

Cytarbel

Cytidin

Cytonal

Cytosar

Cytosar u

Cytosar-u

CytosarU

Cytosar-U

Cytosine 1-beta-D-arabinofuranoside

Cytosine arabinofuranoside

Cytosine arabinose

Cytosine arabinoside

Cytosine arabinoside (VAN)

Cytosine beta-D-arabinofuranoside

Cytosine beta-D-arabinofuranoside hydrochloride

Cytosine beta-D-arabinoside

Cytosine riboside

Cytosine, beta -D-arabinoside

Cytosine, beta-D-arabinoside

Cytosine-1-b-D-arabinofuranoside

Cytosine-1-beta-D-arabinofuranoside

Cytosine-1-beta-D-arabinofuranoside hydrochloride

Cytosine-1-β-D-arabinofuranoside

Cytosinearabinoside

Cytosine-b-D-arabinofuranoside

Cytosine-beta -arabinoside

Cytosine-beta -D-arabinofuranoside

Cytosine-beta-arabinoside

Cytosine-beta-D-arabinofuranoside

cytosine-β-D-arabinofuranoside

Cytosine-β-D-arabinofuranoside

D00168

DB00987

Depocyt

Depocyt (liposomal)

Depocyt (TN)

Depocyte

DepoCyte

EINECS 205-705-9

Erpalfa

FT-0082880

HMS2051K19

HMS2090A18

HSDB 3049

Hydrochloride, cytarabine

Intrathecal (injected into the spinal fluid) DepoCyt

Intrathecal cytarabine (also known as ara-C)

Iretin

Lopac0_000316

LS-860

MLS000758310

MLS001066340

MolPort-001-792-509

NCGC00093356-03

NCGC00093356-04

NCGC00093356-05

NCI-C04728

NSC 287459

NSC287459

S1648_Selleck

SAM001247012

SMR000449317

Spongocytidine

SR-01000075773-3

Tarabine

TL8001048

U 19920A

U-19,920

U-19920

Udicil

UNII-04079A1RDZ

ZINC03795098

Zytidin

19

Antimetabolites

Phase 1

20

Anti-Infective Agents

Phase 1

21

Antiviral Agents

Phase 1

22

Antimitotic Agents

Phase 1

23

Aclacinomycins

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Unknown status	NCT02744742	Phase 2, Phase 3	Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
2	A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent	Recruiting	NCT02562443	Phase 3	rigosertib;Any approved or standard-of-care therapy;best supportive care (BSC);best supportive care (BSC)
3	Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine	Active, not recruiting	NCT01241500	Phase 3	ON 01910.Na
4	A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)	Completed	NCT00854945	Phase 1, Phase 2	ON 01910.Na
5	Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study"	Completed	NCT00744536	Phase 2	Lenalidomide and melphalan
6	Phase I Study of 4'-Thio-araC in Patients With Advanced Hematologic Malignancies	Completed	NCT01139151	Phase 1	3 Day Thiarabine;5 Day Thiarabine
7	A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8	Completed	NCT00533416	Phase 1	ON 01910 Na
8	A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes	Terminated	NCT00458159	Phase 1	CC-11006
9	Effect of Chemotherapy vs No Chemotherapy Pre-transplantation for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS (Bone Marrow Blast Cells Less Than 50%) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Unknown status	NCT02850822		Demethylation drug;Chemotherapy regimen

Search NIH Clinical Center for Refractory Anemia with Excess Blasts Type 1

Sources

Genetic Tests for Refractory Anemia with Excess Blasts Type 1

Sources

Anatomical Context for Refractory Anemia with Excess Blasts Type 1

MalaCards organs/tissues related to Refractory Anemia with Excess Blasts Type 1:

⁴⁰

Myeloid, Bone Marrow, Bone

Sources

Publications for Refractory Anemia with Excess Blasts Type 1

Articles related to Refractory Anemia with Excess Blasts Type 1:

#	Title	Authors	PMID	Year
1	Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature. ⁶¹	Kasi Loknath Kumar A...Kambhampati S	27358895	2016
2	Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. ⁶¹	Gyurkocza B...Deeg HJ	24440648	2014
3	Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. ⁶¹	Font P...Villegas A	22948274	2013
4	[Analysis of immunophenotypic features of blasts in patients with myelodysplastic syndrome by flow cytometry and its diagnostic significance]. ⁶¹	Sun JF...Yang J	22739171	2012
5	Therapy-related myeloid neoplasms following treatment with radioiodine. ⁶¹	Schroeder T...Germing U	21993688	2012
6	Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. ⁶¹	Kuendgen A...Gattermann N	16270213	2005

Sources

Genes for Refractory Anemia with Excess Blasts Type 1

Sources

Variations for Refractory Anemia with Excess Blasts Type 1

Sources

Expression for Refractory Anemia with Excess Blasts Type 1

Search GEO for disease gene expression data for Refractory Anemia with Excess Blasts Type 1.

Sources

Pathways for Refractory Anemia with Excess Blasts Type 1

Sources

GO Terms for Refractory Anemia with Excess Blasts Type 1

Sources

Sources for Refractory Anemia with Excess Blasts Type 1

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia